Abstract:Early prediction of clearance mechanisms allows for the rapid progression of drug discovery and development programs, and facilitates risk assessment of the pharmacokinetic variability associated with drug interactions and pharmacogenomics. Here we propose a scientific framework – Extended Clearance Classification System (ECCS) – which can be used to predict the predominant clearance mechanism (rate-determining process) based on physicochemical properties and passive membrane permeability. Compounds are classified as: Class 1A – metabolism as primary systemic clearance mechanism (high permeability acids/zwitterions with molecular weight (MW) ≤400 Da), Class 1B – transporter-mediated hepatic uptake as primary systemic clearance mechanism (high permeability acids/zwitterions with MW >400 Da), Class 2 – metabolism as primary clearance mechanism (high permeability bases/neutrals), Class 3A –renal clearance (low permeability acids/zwitterions with MW ≤400 Da), Class 3B – transporter mediated hepatic uptake or renal clearance (low permeability acids/zwitterions with MW >400 Da), and Class 4 – renal clearance (low permeability bases/neutrals). The performance of the ECCS framework was validated using 307 compounds with single clearance mechanism contributing to ≥70% of systemic clearance. The apparent permeability across clonal cell line of Madin − Darby canine kidney cells, selected for low endogenous efflux transporter expression, with a cut-off of 5 × 10−6 cm/s was used for permeability classification, and the ionization (at pH7) was assigned based on calculated pKa. The proposed scheme correctly predicted the rate-determining clearance mechanism to be either metabolism, hepatic uptake or renal for ~92% of total compounds. We discuss the general characteristics of each ECCS class, as well as compare and contrast the framework with the biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS). Collectively, the ECCS framework is valuable in early prediction of clearance mechanism and can aid in choosing the right preclinical tool kit and strategy for optimizing drug exposure and evaluating clinical risk of pharmacokinetic variability caused by drug interactions and pharmacogenomics.

Research Progress on Veterinary Drug Biopharmaceutics Classification System ( BCS)

Application prospect of biopharmaceutical classification system based on drug solubility and permeability determination in veterinary drug development

Introduction of Biopharmaceutics Classification System(bcs)and Its Application Progress

The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension

[Research and development thought on biopharmaceutics classification system of Chinese materia medica].

Considerations for application of biopharmaceutics classification system in chicken: Exemplified by seven drugs classification.

State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References

Technical Requirements for Biopharmaceutics Classification System-Based Biowaiver in China

Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System

Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System

Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls

iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System

Application of physiologically based pharmacokinetic models to promote the development of veterinary drugs with high efficacy and safety

COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.

Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)

ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries

Simulation-based comparison of Biopharmaceutics Classification System and drug structure

[Research on attributes of biopharmaceutics classification system for Chinese materia medica of baicalein in Gegen Qinlian Decoction environment].

Insight into Delivery Approaches for Biopharmaceutics Classification System Class II and IV Drugs

Research Progress on New Preparation Technologies for Improving Solubility and Permeability of Drugs

Intelligent Veterinary Drug Information Management System: Architecture, Technology and Application